Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study-论文-万方医学网

首页> > Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study

导出原文传递

翻译打印收藏纠错

第一作者： Derman, Benjamin A.

作者： Derman, Benjamin A. ^[1] ; Kansagra, Ankit ^[2] ; Zonder, Jeffrey ^[3] ; Stefka, Andrew T. ^[4] ; Grinblatt, David L. ; Anderson, Larry D., Jr. ; Gurbuxani, Sandeep ; Narula, Sunil ; Rayani, Shayan ; Major, Ajay ; Kin, Andrew ; Jiang, Ken ; Karrison, Theodore ; Jasielec, Jagoda ; Jakubowiak, Andrzej J.

作者单位： University of Chicago,Univ Chicago ^[1] Karmanos Canc Inst,Wayne State Univ ^[2] Simmons Comprehens Canc Ctr,UT Southwestern Med Ctr ^[3] NorthShore Univ Hlth Syst ^[4]

关键词 MASS-SPECTROMETRY OPEN-LABEL BORTEZOMIB TRIAL MAINTENANCE COMBINATION MULTICENTER DARATUMUMAB ENDURANCE

发布时间 2022-12-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study

相似文献

同项目论文

相关期刊

检索历史 清除

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent A Phase 2 Measurable Residual Disease-Adapted Study

相似文献

同项目论文

相关期刊

检索历史清除